He put public notice for businesses. By 28 February the presentation of projects in the health sector
MISE press release - 19 January 2022
Realize industrial autonomy in strategic health sector, ensuring Italy and the European Union an integrated supply chain between companies capable of developing and producing highly innovative products: drugs, vaccines, therapies and medical devices to prevent and combat health crises such as Covid-19 or diseases that require new treatments and for which it is necessary to strengthen the health system by investing in biotechnologies, nanotechnologies, but also in the digitization of production processes and in the development of platforms that favor digital therapies.
This is what theImportant Project of Common European Interest (IPCEI) on health that the Ministry of Economic Development led by Giancarlo Giorgetti has undertaken to build as part of the industrial policy initiatives promoted by our country together with the other EU member states and the European Commission.
The issue of health is in fact one of the pillars of the industrial development strategy pursued by Minister Giorgetti who has deployed new resources and tools, such as the Enea Tech and Biomedical Foundation, to support investments in research and technology transfer in our country, but he also promoted, in the bilateral meetings with the EU Commissioner Breton, the French Minister Le Maire and the other representatives of the Member States received at the Mise, the need to create a joint European action plan to strengthen strategic autonomy in a sector that the pandemic has revealed to be of primary importance.
“The Italian pharmaceutical industry is a candidate to be a point of reference at European level. Since the beginning of my mandate, I have relied heavily on the excellence of our pharmaceutical industries. I am confident that everyone's efforts and commitment will soon bear fruit”, declares Giorgetti.
“We want to implement a common project of EU interest in the health sector – continues the minister – because the Covid emergency has made us understand how much of a priority it is to launch an extraordinary investment support plan, in which Italian companies will be able to play a leading role thanks to their skills and expertise“.
“The IPCEI on health – concludes Giorgetti – it is a first concrete step forward in the definition of a common European strategy in which Italy plays a very important role both at an industrial level and in terms of technology transfer in a frontier sector such as the pharmaceutical and medical sectors“.
Companies interested in participating in the IPCEI will be able to respond to theI notify published by the Mise by posting, starting today January 19th and no later than February 28, 2022, its manifestation of interest by proposing an investment project in Italy which, in addition to research and development activities, must also have an experimental phase of industrial development.
The projects to come selected they can be financed in derogation from the European legislation on state aid, to face market and social challenges that could not be overcome in any other way, but possibly also with resources from the National Recovery and Resilience Plan if the related activities comply with environmental legislation national and European.
For more information
Information documents on the IPCEI tool and for compiling the required documents
- IPCEI Communication 2021 (Doc. C (2021) 8481 final of 25 November 2021) – in English (pdf)
- IPCEI Tool Illustrative Document (pdf)
- Informal Guidance On Spillover Effects (pdf)
- Funding Gap Guidance (pdf)
- template (example - not to be filled in) (xlsx)
Applicable projects
The purpose of this call for expressions of interest is to identify the projects eligible to participate in the IPCEI. Interested parties are invited to submit a formal expression of interest for projects that meet one or more of the objectives, including but not limited to, indicated below:
- Prevention and contrast to health crises and the spread of highly prevalent and/or emergency diseases that require new treatments (cardiovascular, oncological, degenerative, infectious and genetic) thanks to advanced bio-nanotechnologies for the development of innovative vaccines and adjuvants, medical devices, active ingredients and drugs of a chemical, biological and biotechnological nature, also with a view to industrial reshoring and strengthening of national and European strategic autonomy;
- Product innovation and personalized medicine, through projects aimed at developing and producing medical devices and diagnostic tests, drugs based on biological macromolecules and chemical compounds and related delivery systems, cell therapies for immunotherapy and regenerative medicine, aimed at making new research, diagnosis and treatment approaches possible ( including precision medicine platforms for decentralized and international clinical trials), with the aim of strengthening the healthcare system in Italy and in Europe;
- Innovation in production processes through highly sustainable and digitalisation projects (e.g. smart manufacturing, Industry 4.0, robotics, drug screening and repurposing) which lead to an increase in production capacity, added value and competitiveness, a reduction in R&D costs and times and in production with the aim the strengthening of national and European strategic autonomy;
- Countering antimicrobial resistance and the development of resistant bacterial strains, with research and production projects aimed at increasing therapeutic options, improving access to therapy, strengthening the health system in Italy and in Europe;
- Digital Health, with the development of platforms and Artificial Intelligence for R&D, digital therapeutics, Real World Data analysis for the purpose of prevention and improvement of access and treatment pathways in Italy and Europe.
